[go: up one dir, main page]

UY37149A - 2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas - Google Patents

2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas

Info

Publication number
UY37149A
UY37149A UY0001037149A UY37149A UY37149A UY 37149 A UY37149 A UY 37149A UY 0001037149 A UY0001037149 A UY 0001037149A UY 37149 A UY37149 A UY 37149A UY 37149 A UY37149 A UY 37149A
Authority
UY
Uruguay
Prior art keywords
dihydroimidazo
carboxamids
pirimidin
metoxi
quinazolin
Prior art date
Application number
UY0001037149A
Other languages
English (en)
Inventor
Thomas Schwarz Dr
Ningshu Liu
Oliver Politz
Michael Gerisch
Dieter Lang
Andreas Lender
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY37149A publication Critical patent/UY37149A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos de 2,3–dihidroimidazo[1,2–c]quinazolina novedosos, composiciones farmacéuticas que contienen dichos compuestos y al uso de dichos compuestos o composiciones para la inhibición de fosfatidilinositol–3–quinasa (PI3K) y para el tratamiento de enfermedades asociadas con la actividad de fosfatidilinositol–3–quinasa (PI3K), en particular para el tratamiento de trastorno hiperproliferativos y/o angiogénicos, como único agente o en combinación con otros ingredientes activos.
UY0001037149A 2016-03-08 2017-03-08 2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas UY37149A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16159156 2016-03-08

Publications (1)

Publication Number Publication Date
UY37149A true UY37149A (es) 2017-10-31

Family

ID=55521577

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037149A UY37149A (es) 2016-03-08 2017-03-08 2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas

Country Status (9)

Country Link
US (1) US10844066B2 (es)
EP (1) EP3426657B1 (es)
JP (1) JP6935415B2 (es)
CN (1) CN108884098B (es)
AR (1) AR107828A1 (es)
CA (1) CA3016584A1 (es)
TW (1) TW201736375A (es)
UY (1) UY37149A (es)
WO (1) WO2017153220A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
JP6867295B2 (ja) 2015-03-09 2021-04-28 バイエル ファーマ アクチエンゲゼルシャフト 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
JP2019532922A (ja) 2016-09-23 2019-11-14 バイエル ファーマ アクチエンゲゼルシャフト Ｐｉ３ｋ−阻害剤の組み合わせ
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3054249A1 (en) * 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
FR3072024A1 (fr) * 2017-10-11 2019-04-12 Olivier Petitjean Prevention et traitement de l’hyperplasie benigne de la prostate a l‘aide d’un inhibiteur selectif de la production d’especes reactives de l’oxygene d’origine mitochondriale
KR102618168B1 (ko) * 2018-07-06 2023-12-27 일양약품주식회사 프리온 질환의 예방 또는 치료를 위한 약제학적 조성물
CN109674817B (zh) * 2019-01-31 2021-06-29 哈尔滨医科大学 三氧化二砷在制备治疗晚期动脉粥样硬化药物中的用途
CN110656152A (zh) * 2019-10-11 2020-01-07 郑州大学 一种艾曲波帕介导巨噬细胞抗血管生成作用验证方法
CN114223613B (zh) * 2021-11-30 2023-03-21 西安医学院 一种基于aav8-pcsk9诱导的高胆固醇血症和动脉粥样硬化小鼠模型及构建方法
WO2025006391A1 (en) * 2023-06-26 2025-01-02 Athos Therapeutics, Inc. Small molecules for the treatment of autoimmune disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20131159B1 (hr) 2002-09-30 2019-11-01 Bayer Ip Gmbh Taljeni azol-pirimidin derivati
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
US8859572B2 (en) 2008-01-14 2014-10-14 Bayer Intellectual Property Gmbh Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
CN102958540B (zh) 2010-04-16 2015-09-02 拜耳知识产权有限责任公司 含取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
US9999623B2 (en) 2013-04-08 2018-06-19 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
EP3077002B1 (en) 2013-12-03 2020-04-22 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
JP6867295B2 (ja) 2015-03-09 2021-04-28 バイエル ファーマ アクチエンゲゼルシャフト 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ
BR112017019190A2 (pt) 2015-03-09 2018-04-24 Bayer Healthcare Pharmaceuticals Inc uso de 2,3-di-hidroimidazo[1,2-c]quinazolinas substituídas
JP2019512003A (ja) 2016-02-01 2019-05-09 バイエル ファーマ アクチエンゲゼルシャフト コパンリシブバイオマーカー
US20190038632A1 (en) 2016-02-01 2019-02-07 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
JP2019532922A (ja) 2016-09-23 2019-11-14 バイエル ファーマ アクチエンゲゼルシャフト Ｐｉ３ｋ−阻害剤の組み合わせ

Also Published As

Publication number Publication date
US20190092775A1 (en) 2019-03-28
CN108884098A (zh) 2018-11-23
US10844066B2 (en) 2020-11-24
WO2017153220A1 (en) 2017-09-14
EP3426657A1 (en) 2019-01-16
JP2019507770A (ja) 2019-03-22
CA3016584A1 (en) 2017-09-14
CN108884098B (zh) 2021-09-14
TW201736375A (zh) 2017-10-16
EP3426657B1 (en) 2022-07-13
JP6935415B2 (ja) 2021-09-15
AR107828A1 (es) 2018-06-13

Similar Documents

Publication Publication Date Title
UY37149A (es) 2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
CO2019004137A2 (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CL2018002920A1 (es) Nuevos derivados de pirazolopirimidina
CO2020001242A2 (es) Dihidrooxadiazinonas
SV2009003288A (es) Derivados de 2, 3-dihidroimidazo [1,2-c] quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
CO2022007005A2 (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
UY37789A (es) Nuevos derivados de azaquinolina
UY37705A (es) Nuevos derivados de pirazol bicíclicos
DOP2022000031A (es) [1,2,4]triazolo[1,5-c]quinazolin-5-aminas
UY37971A (es) Derivados de indol macrocíclicos sustituidos
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
BR112018074381A2 (pt) [8-(fenil sulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il] (1h-1,2,3-triazol-4-il)metanonas
MX2020004105A (es) Formulacion farmaceutica.
TN2013000204A1 (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230601